Heart failure & cardiomyopathies
Prognostic Value of Plasma soluble AXL (sAXL) in Patients with Heart Failure: Insights from the DRAGON-HF Trial
Main finding · Primary endpoint per 1-SD increment of sAXLResult — go to the resultHazard ratio 1.128 CI 1.024–1.242Authors' conclusion
Plasma sAXL concentrations are of great importance in predicting clinical outcomes in HF patients, independent of NT-proBNP
Study context
- Population
- Patients with symptomatic heart failure (HF)
- Participants
- 1,030 patients
- Exposure
- Plasma sAXL level
- Outcome
- Composite of:
- CV mortality
- HF rehospitalization
- Follow-up
- Median 32 months
Methodological detailsmulticentre, observational
- Multicentre
- Observational
Main finding
Primary endpoint per 1-SD increment of sAXL
Hazard ratio
1.128
CI 1.024–1.242
1-SD increment of sAXL
HR 1.128 (CI 1.024–1.242)
Per 1-SD increment of sAXL, as printed
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (CI) | |
|---|---|---|
| CV mortality, all-cause mortality, HF rehospitalization per 1-SD increment of sAXL1-SD increment of sAXL · CV mortality · adjusted for confounders incl. NT-proBNP | 1.112 (1.032–1.198) | |
| CV mortality, all-cause mortality, HF rehospitalization per 1-SD increment of sAXL1-SD increment of sAXL · all-cause mortality · adjusted for confounders incl. NT-proBNP | 1.142 (1.057–1.234) | |
| CV mortality, all-cause mortality, HF rehospitalization per 1-SD increment of sAXL1-SD increment of sAXL · HF rehospitalization · adjusted for confounders incl. NT-proBNP | 1.122 (1.030–1.224) | |
| 0.512Hazard ratio (log scale) |
Baseline sAXL · admission
- Mean baseline sAXL 20.03 ± 6.74 ng/mL
Correlates of sAXL
- Positively associated with NYHA class, negatively with LVEF
- P < 0.001
Kaplan-Meier by sAXL level
- Highest sAXL levels at highest risk of primary endpoint, CV mortality and all-cause mortality
- P < 0.001
Combined sAXL and NT-proBNP
- Combined use more likely to predict all-cause or CV mortality
- P < 0.001
By LVEF (HFrEF, HFmrEF, HFpEF)
- Similar results across HFrEF, HFmrEF and HFpEF
Original publication
Prognostic Value of Plasma sAXL in Patients with Heart Failure: Insights from the DRAGON-HF Trial. ESC Heart Fail. Published 27 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →